As Novartis AG reported another very strong quarter for Entresto, the Swiss major does not think that the advent of competition from the SGLT2 inhibitor class for heart failure (HF) patients will have much effect on the cardiovascular drug's peak sales target of around $5bn.
Novartis's second quarter results unveiled on 21 July revealed that sales of Entresto (sacubitril/valsartan) soared by 46% at constant currencies...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
